Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 19 of 30
Active Surveillance of the Small Renal Mass
NCT02204800
Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation
NCT02317731
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
NCT02236572
The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism
NCT02262026
Continuous Glucose Monitoring in Youth With Type 2 Diabetes
NCT02293577
Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)
NCT02310152
The Human Microbiome in Immune-Mediated Diseases
NCT02394964
Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
NCT02266355
GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
NCT02302976
Biological Biomarkers in MOMS Partnership
NCT02438514
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents
NCT02499705
Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1
NCT02179034
Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery
NCT02402023
Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial
NCT02256670
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients
NCT02267733
Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults
NCT02498145
Smartphone Application for Smoking Cessation
NCT02134509
Automated Bilingual Computerized Alcohol Screening and Intervention in Latinos (AB-CASI)
NCT02247388
The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis
NCT02282878
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity and Preference - Pilot
NCT02335008
Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception
NCT02238379
Loss of Control Eating Following Weight Loss Surgery
NCT02259322
Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System
NCT02262039
Neural Mechanisms of CBT for Anxiety in Autism (Open Pilot Study)
NCT02225808
SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography
NCT02170233
LATCH: Lactation Advice Thru Texting Can Help
NCT02214849
Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
NCT02218879
Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
NCT02152696
A Reinforcement Approach to Improve Diabetes Management
NCT02167243
Irritable Bowel Syndrome and Food Sensitivity
NCT02186743
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
NCT02003820
Varenicline + Prazosin for Heavy Drinking Smokers
NCT02193256
Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer
NCT02178644
Mindfulness Interventions and Chronic Widespread Pain in Adolescents
NCT02190474
PET Imaging in Cocaine Self Administration
NCT02181491
Tofacitnib for the Treatment of Alopecia Areata and Variants
NCT02197455
Improving Cancer Family Caregivers' Knowledge and Communication About Care Options
NCT02616107
Cirrhosis Readmission Telehealth Project
NCT02313896
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
NCT03583138
Computerized Cognitive Behavioral Therapy and Electroconvulsive Therapy
NCT02176473
Integrating Palliative Care Into Self-Management of Breast Cancer
NCT02148575
Does Guanfacine Attenuate Stress-Induced Drinking?
NCT02164422
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
NCT02134522
N-acetylcysteine Effects on Tetrahydrocannabinol
NCT02335060
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
NCT02110706
Prostate Cancer Screening in Men With Germline BRCA2 Mutations
NCT02154672
Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study
NCT02081144
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872
FAAH Inhibitor Trial for Adults With Tourette Syndrome
NCT02134080
Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET
NCT02152670
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.